Trial reportNaunyn-Schmiedeberg's archives of pharmacology2025
Bioequivalence evaluation of dexamethasone palmitate injections by intravenous injection in healthy Chinese volunteers: a 2-period crossover trial.
Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Dexamethasone palmitate injection is used mainly in the treatment of severe rheumatoid arthritis. This study aimed to compare the bioequivalence and safety profiles of two (1 mL:4 mg) dexamethasone palmitate injections in the fasting arm in healthy Chinese volunteers. A random, open, single-dose, two-preparation, two-sequence, two-period crossover design was conducted. Twenty-four healthy volunteers participated in the study. Each participant received an intravenous injection of either the test (imitation) or reference (original) formulation of dexamethasone palmitate in the fasting arm during each study period, with a 7-day washout period between administrations. The results showed that, under the fasting condition, the pharmacokinetic parameters of the test and reference formulations were within the acceptable limits for bioequivalence. The 90% confidence intervals for the ratios of C
Indexed as
Identifiers
40536552What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.